From In Vitro to Perioperative Vascular Tissue Engineering: Shortening Production Time by Traceable Textile-Reinforcement.
Electrospun scaffolds
Non-invasive monitoring
Tissue-engineered vascular grafts
Journal
Tissue engineering and regenerative medicine
ISSN: 2212-5469
Titre abrégé: Tissue Eng Regen Med
Pays: Korea (South)
ID NLM: 101699923
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
28
04
2022
accepted:
20
07
2022
revised:
18
07
2022
pubmed:
7
10
2022
medline:
24
11
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
The production of tissue-engineered vascular graft (TEVG) usually involves a prolonged bioreactor cultivation period of up to several weeks to achieve maturation of extracellular matrix and sufficient mechanical strength. Therefore, we aimed to substantially shorten this conditioning time by combining a TEVG textile scaffold with a recently developed copolymer reinforced fibrin gel as a cell carrier. We further implemented our grafts with magnetic resonance imaging (MRI) contrast agents to allow the in-vitro monitoring of the TEVG's remodeling process. Biodegradable polylactic-co-glycolic acid (PLGA) was electrospun onto a non-degradable polyvinylidene fluoride scaffold and molded along with copolymer-reinforced fibrin hydrogel and human arterial cells. Mechanical tests on the TEVGs were performed both instantly after molding and 4 days of bioreactor conditioning. The non-invasive in vitro monitoring of the PLGA degradation and the novel imaging of fluorinated thermoplastic polyurethane ( After 4 days of close loop bioreactor conditioning, 617 ± 85 mmHg of burst pressure was achieved, and advanced maturation of extracellular matrix (ECM) was observed by immunohistology, especially in regards to collagen and smooth muscle actin. The suture retention strength (2.24 ± 0.3 N) and axial tensile strength (2.45 ± 0.58 MPa) of the TEVGs achieved higher values than the native arteries used as control. The contrast agents labeling of the TEVGs allowed the monitorability of the PLGA degradation and enabled the visibility of the non-degradable textile component. Here, we present a concept for a novel textile-reinforced TEVG, which is successfully produced in 4 days of bioreactor conditioning, characterized by increased ECM maturation and sufficient mechanical strength. Additionally, the combination of our approach with non-invasive imaging provides further insights into TEVG's clinical application.
Sections du résumé
BACKGROUND
The production of tissue-engineered vascular graft (TEVG) usually involves a prolonged bioreactor cultivation period of up to several weeks to achieve maturation of extracellular matrix and sufficient mechanical strength. Therefore, we aimed to substantially shorten this conditioning time by combining a TEVG textile scaffold with a recently developed copolymer reinforced fibrin gel as a cell carrier. We further implemented our grafts with magnetic resonance imaging (MRI) contrast agents to allow the in-vitro monitoring of the TEVG's remodeling process.
METHODS
Biodegradable polylactic-co-glycolic acid (PLGA) was electrospun onto a non-degradable polyvinylidene fluoride scaffold and molded along with copolymer-reinforced fibrin hydrogel and human arterial cells. Mechanical tests on the TEVGs were performed both instantly after molding and 4 days of bioreactor conditioning. The non-invasive in vitro monitoring of the PLGA degradation and the novel imaging of fluorinated thermoplastic polyurethane (
RESULTS
After 4 days of close loop bioreactor conditioning, 617 ± 85 mmHg of burst pressure was achieved, and advanced maturation of extracellular matrix (ECM) was observed by immunohistology, especially in regards to collagen and smooth muscle actin. The suture retention strength (2.24 ± 0.3 N) and axial tensile strength (2.45 ± 0.58 MPa) of the TEVGs achieved higher values than the native arteries used as control. The contrast agents labeling of the TEVGs allowed the monitorability of the PLGA degradation and enabled the visibility of the non-degradable textile component.
CONCLUSION
Here, we present a concept for a novel textile-reinforced TEVG, which is successfully produced in 4 days of bioreactor conditioning, characterized by increased ECM maturation and sufficient mechanical strength. Additionally, the combination of our approach with non-invasive imaging provides further insights into TEVG's clinical application.
Identifiants
pubmed: 36201158
doi: 10.1007/s13770-022-00482-0
pii: 10.1007/s13770-022-00482-0
pmc: PMC9679079
doi:
Substances chimiques
Contrast Media
0
Fibrin
9001-31-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1169-1184Informations de copyright
© 2022. The Author(s).
Références
Curr Pharm Biotechnol. 2007 Feb;8(1):43-50
pubmed: 17311552
Biofabrication. 2017 Aug 17;9(3):035007
pubmed: 28817384
Acta Biomater. 2015 Jan;11:114-25
pubmed: 25305234
J Mater Sci Mater Med. 2021 Mar 1;32(2):21
pubmed: 33649939
Tissue Eng Part A. 2009 May;15(5):1081-9
pubmed: 18831688
Acta Biomater. 2009 Jan;5(1):305-15
pubmed: 18778977
Tissue Eng Part A. 2014 May;20(9-10):1499-507
pubmed: 24320793
J Tissue Eng. 2021 Nov 29;12:20417314211057236
pubmed: 34868539
Eur J Cardiothorac Surg. 2001 Jul;20(1):164-9
pubmed: 11423291
Eur J Cardiothorac Surg. 2012 Jan;41(1):167-72
pubmed: 21530291
Biomaterials. 2019 Sep;216:119228
pubmed: 31195299
Tissue Eng Part A. 2009 Sep;15(9):2665-76
pubmed: 19207043
Cells Tissues Organs. 2012;195(1-2):60-72
pubmed: 21996715
RSC Adv. 2019 Jul 9;9(37):21258-21264
pubmed: 35521332
Nat Rev Dis Primers. 2018 Oct 18;4(1):34
pubmed: 30337540
PLoS One. 2021 Mar 12;16(3):e0248346
pubmed: 33711057
Tissue Eng Part A. 2013 Mar;19(5-6):583-92
pubmed: 23286285
Magn Reson Med. 2008 Nov;60(5):1066-72
pubmed: 18956457
Vasc Endovascular Surg. 2018 Apr;52(3):181-187
pubmed: 29421969
Nat Protoc. 2016 Oct;11(10):1775-81
pubmed: 27583639
Biomacromolecules. 2019 Feb 11;20(2):992-1006
pubmed: 30608144
J Vasc Surg. 2001 Mar;33(3):628-38
pubmed: 11241137
Magn Reson Med. 2007 Oct;58(4):725-34
pubmed: 17899609
ACS Appl Mater Interfaces. 2018 Aug 1;10(30):25056-25068
pubmed: 29965724
Cardiovasc Pathol. 2003 Mar-Apr;12(2):59-64
pubmed: 12684159
Artif Organs. 2008 Oct;32(10):800-9
pubmed: 18684200
Biomaterials. 2011 Jan;32(3):714-22
pubmed: 20934214
Biomed Res Int. 2013;2013:390518
pubmed: 23971031
Adv Sci (Weinh). 2022 Apr;9(10):e2105783
pubmed: 35119216
MAGMA. 2019 Feb;32(1):25-36
pubmed: 30097741
Pharm Res. 2008 May;25(5):1212-21
pubmed: 18092140
Trends Biotechnol. 2010 Jul;28(7):363-70
pubmed: 20427096
J Vasc Surg. 1987 Sep;6(3):235-9
pubmed: 2957513
Chem Mater. 2017 Apr 11;29(7):2669-2671
pubmed: 28413258
Adv Funct Mater. 2014 Feb 12;24(6):754-762
pubmed: 24569840
Ann Biomed Eng. 2018 Apr;46(4):616-626
pubmed: 29340931
Tissue Eng Part A. 2009 Aug;15(8):1909-18
pubmed: 19125650
J Nucl Med. 2014 Mar;55(3):392-5
pubmed: 24516259
Arch Phys Med Rehabil. 1995 May;76(5):457-62
pubmed: 7741618
FASEB J. 1998 Jan;12(1):47-56
pubmed: 9438410
Tissue Eng Part A. 2012 Aug;18(15-16):1608-16
pubmed: 22462723
Chem Commun (Camb). 2011 Mar 14;47(10):2826-8
pubmed: 21240412
Ann Plast Surg. 2013 Jun;70(6):680-3
pubmed: 22868324
Curr Eye Res. 2018 Jan;43(1):1-11
pubmed: 29281419
Tissue Eng Part C Methods. 2018 Aug;24(8):465-473
pubmed: 29978768
Science. 1999 Apr 16;284(5413):489-93
pubmed: 10205057
ACS Nano. 2019 Mar 26;13(3):2969-2985
pubmed: 30758189
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2227-33
pubmed: 24952823
Facial Plast Surg. 1996 Jan;12(1):3-7
pubmed: 9244000
Tissue Eng Part C Methods. 2012 Dec;18(12):976-83
pubmed: 22697487
J Am Chem Soc. 2008 Nov 19;130(46):15678-82
pubmed: 18950162
Biomed Mater. 2011 Oct;6(5):055001
pubmed: 21813957
Int J Mol Med. 2016 Nov;38(5):1319-1326
pubmed: 27666161
Med Biol Eng Comput. 2007 Apr;45(4):327-36
pubmed: 17340153
APL Bioeng. 2021 May 07;5(2):021507
pubmed: 33981941
Magn Reson Med. 2009 Sep;62(3):747-53
pubmed: 19585593
Biomaterials. 2019 Dec;223:119461
pubmed: 31518843